Log In
BCIQ
Print this Print this
 

MGD015

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionBispecific antibody against CD3 and an undisclosed target
Molecular Target CD3 ; Undisclosed
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$740.0M

$75.0M

$665.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/18/2016

$740.0M

$75.0M

$665.0M

Get a free BioCentury trial today